Clinical Trials List
2021-05-20 - 2025-12-31
Phase IV
Recruiting2
ICD-10D82.2
Immunodeficiency with short-limbed stature
ICD-10D82.3
Immunodeficiency following hereditary defective response to Epstein-Barr virus
ICD-10D82.4
Hyperimmunoglobulin E [IgE] syndrome
ICD-10D82.8
Immunodeficiency associated with other specified major defects
ICD-10D82.9
Immunodeficiency associated with major defect, unspecified
ICD-10D84.0
Lymphocyte function antigen-1 [LFA-1] defect
ICD-10D84.1
Defects in the complement system
ICD-10D89.3
Immune reconstitution syndrome
ICD-10D89.89
Other specified disorders involving the immune mechanism, not elsewhere classified
ICD-10M35.9
Systemic involvement of connective tissue, unspecified
ICD-9279.8
Other specified disorders involving the immune mechanism
-
Trial Applicant
IQVIA RDS Taiwan Ltd.
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2025/08/20
Investigators and Locations
Co-Principal Investigator
- MING YAO Division of Hematology & Oncology
- CHENG-HONG TSAI Division of Hematology & Oncology
- Chieh-Lung Cheng Division of Hematology & Oncology
- Tai-Chung Huang Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Tzu-Ting Chen Division of Hematology & Oncology
- Ming-Yu Lien Division of Hematology & Oncology
- Ching-Chan Lin Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
3 participants
-
Global
500 participants
